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Summary Tumour necrosis factor (TNF) has been found to be an important immunomodulator. Among
other functions TNF activates natural killer (NK) cells and stimulates monocytes/macrophages in an autocrine
fashion. TNF production and NK activity in peripheral blood mononuclear cells were determined in a clinical
phase I study in which recombinant human (rh) TNF was administered as a continuous infusion weekly for a
period of 8 weeks. Even though TNF production and NK activity were significantly reduced directly after
rhTNF infusion the effect proved to be transient and most pronounced at the first rhTNF administration. One
day after completion of the rhTNF infusion the peripheral cells released more TNF into the supernatant
compared to TNF activity immediately before the rhTNF infusion. This effect was conspicuous in non-
stimulated cultures. After repeated rhTNF infusions both stimulated and non-stimulated TNF production of
the peripheral blood mononuclear cells was increased. NK cell activity was also enhanced after repeated cycles
of rhTNF administration as compared to early rhTNF treatment. Thus, repeated rhTNF infusions lead to a
stimulatory effect on TNF production and NK activity of peripheral blood cells.
Lymphocytes and macrophages release an array of soluble
mediators (cytokines) which affect immune responses. The
major activities of some of these mediators are activation of
cells and the induction or support of proliferative or suppres-
sive effects. Most of the structurally defined mediators have a
broad sprectrum of activities overlapping with functions of
other mediators. Activated macrophages release
inflammatory mediators like interleukin 1 (ILl) and tumour
necrosis factor (TNF) which both have a pleiotropic mode of
action. In vivo, TNF induces fever, hypotension, leukopenia,
local tissue necrosis (Chapman et al., 1987) and can lead to a
vascular leak syndrome (Remick et al., 1987). The same
effects can be induced with ILl. Many of the biological
effects of TNF and ILl overlap and the two monokines can
act in a synergistic manner. Induction of the arachidonic acid
metabolism, catabolic processes, inhibition of lipoprotein
lipase, increase in hepatic acute phase reactants, and neut-
rophil activation have been demonstrated with both TNF
and ILl as reviewed by Dinarello (1987). Many of the
endotoxic effects of TNF and ILl come about by the interac-
tion of the mediators with endothelial cells. TNF and ILl
damage the endothelial cell layer, induce PGE2 and platelet
activating factor production, procoagulant activity, leukocyte
adherence and plasminogen activator inhibitor (Dinarello,
1987).
Since one of the effects of TNF in vitro as well as in vivo is
its antitumour action, several clinical studies were started
once purified recombinant human TNF (rhTNF) became
available. For one of these studies the detailed protocol and
the clinical outcome have been described recently (Weiden-
mann et al., 1989). It seemed reasonable to assume that some
of the immunomodulating effects of TNF might also be
induced after repeated infusion of increasing amounts of
rhTNF in patients in this trial. Therefore, two immunological
parameters which might be affected by TNF have been tested
in the peripheral blood of patients before and after rhTNF
treatment during therapy. Monocyte/macrophage activation
for monokine production (Philip & Epstein, 1986; Bachwich
et al., 1986; Hensel et al., 1987) and enhanced NK activity
(Ostensen et al., 1987) has been demonstrated with TNF in
experimental systems. Here we demonstrate that also in vivo
the capacity of peripheral blood mononuclear leukocytes
(PMNL) for TNF release and the NK activity was enhanced
during therapy with rhTNF. The observation of an early
drop in monokine production and NK activity directly after
rhTNF infusion as described recently (Kist ct al., 1988) was
of short duration and followed by enhanced activity of both
monocytes and NK cells.
Material and methods
Patients
Patients in this study were treated with rhTNF in a phase I
clinical trial. Patients were eligible for the study if they had
progressive neoplastic diseases refractory to standard
chemotherapy regimens and no alternative treatment was
available. They had to have an ECOG performance status of
<2, normal renal and normal hepatic functions, and no
evidence for active infections. No cytostatic or
immunosupressive drugs were given for at least 6 weeks
before rhTNF treatment.
Eligible patients were assigned at random to two regimen
arms: in arm A, patients received a continuous i.v. infusion
of rhTNF for 24 h once a week (Mondays) for 8 weeks; in
arm B, patients received the same dosage of rhTNF in a 24 h
infusion twice a week (Mondays and Thursdays) for 8 weeks.
The initial dose for each patient was 0.04 mg m-2 24 h-', and
subsequent doses were escalated each week according to a
Fibonacci scale until maximum therapeutic dose (MTD) for
the patient was reached.
The protocol of the clinical trial was approved by the
Ethics Commission of the Faculty of the University of
Heidelberg, FRG. Informed consent was obtained from each
patient before accrual into the clinical trial and the
laboratory studies. Altogether eight patients were studied for
NK activity and monokine production: all patients had ref-
ractory colorectal carcinoma. Their median age was 54 years
(range 23-67 years). Seven patients were male and one was
female. Patients 6 and 7 received paracetamol, patients 3 and
4 received indomethacin and patients I and 2 received both.
The clinical observations during this study have been pub-
lished recently (Wiedenmann et al., 1989).
Correspondence: D.Mannel, Institute of Immunology and Genetics,
German Cancer Research Centre, Im Neuenheimer Feld 280, 6900
Heidelberg, FRG.
Received 13 October 1988; and in revised form 8 June 1989.
Br. J. Cancer (1989), 60, 585-588 'PI The Macmillan Press Ltd., 1989586 D.N. MANNEL et al.
Reagents
rhTNF was supplied by Knoll/BASF AG, Ludwigshafen,
FRG. The specific activity of the material was
9 x I07 U mg-1 protein as measured in the biological tumour
cell (L929) cytotoxicity assay in the presence of actinomycin
D as described recently (Andus et al., 1987). The pyrogen
content was less than 1.3ngmg-' protein.
Preparation ofPMNL
Human PMNL were prepared from heparinised blood sam-
ples by Ficoll-Paque (Pharmacia, Freiburg, FRG) density
gradient centrifugation.
Determination of TNFproduction capacity
PMNL (2 x 106ml-') were cultured in duplicates in
RPMI1640 (Gibco), with 10% heat inactivated fetal calf
serum (Gibco) for 20 h either with or without 10 lg ml-'
Staphylococcus aureus (Staph.a., Pansorbin, Calbiochem,
Frankfurt, FRG). Cell-free supernatants were harvested and
stored at -20°C until they were tested for TNF activity.
TNF activity was determined in duplicates by an enzyme-
linked immunospecific assay (ELISA) as described recently
(Kist et al., 1988). The standard deviation was always< 3%.
TNF content was expressed as ng ml-'. The lowest amount
of TNF detectable with this assay was 340 ± 180 pg ml-'.
Determination ofNK activity
NK activity in the PMNL was determined as described
recently (Kist et al., 1988). Briefly, % specific lysis of5"Cr-
labelled target cells (K562 tumour cells) by the PMNL was
determined in triplicate cultures at effector to target ratios of
10:1, 5:1, and 2.5:1 after 4h of incubation. The standard
deviation was always < 5%.
RNA extraction and dot blot analyses
The procedure has been described in detail recently (Cheley
& Anderson, 1984). Cells (106 per culture) were solubilised
with I ml 7.6 M guanidine-HCI in 0.1M potassium acetate
buffer pH5 and homogenised by 5 times aspiration through a
21 gauge needle. Ninety-five per cent ethanol (0.6 ml) was
admixed and RNA precipitated at -20°C during 12 h. RNA
was pelleted by 20 min, centrifugation at 5000 g, the pellet
dissolved in 150 fig 15% formaldehyde and 150jil 20 x SSC
(I x SSC (standard saline citrate) is 0.1 M sodium chloride,
0.015 M sodium citrate) was added. The solution was heated
15 min at 50°C and chilled on ice. Serial dilutions (log 2)
were applied to nylon filters (Compas, Genofit, Heidelberg,
FRG) pre-wetted with water and 10 x SSC. The RNA was
fixed on the nylon filters by exposure to UV light for 2 min
and hybridisation was performed according to the method
described in detail by Khandijan (1986) at 42°C in the
presence of dextransulfate. The filters were washed twice
under high stringency conditions (65°C, 30 min, 2 x SSC con-
taining 1 %SDS). Probes were labelled with 32P-GTP and
-CTP (Amersham, Frankfurt, FRG, specific activity
3000 Ci mmol-') by the random primer method using a hex-
amer (Pharmacia, Freiburg, FRG). The TNF-cDNA probe
consisted of a 425 bp PstI-fragment of the non-translated
3'-region of human TNF and was obtained from BASF,
Ludwigshafen, FRG. The human P-actin-cDNA probe is
described by Moos and Gallwitz (1983) and consists of an
560 bp SalI-EcoRI cDNA fragment.
Statistics
Statistical analyses of the data pairs from individual patients
obtained before and after rhTNF treatment were performed
using the Wilcoxon rank sum test. P values were calculated
for assessment of significance.
Results
TNF production capacity of seven patients was determined
during 31 cycles of rhTNF treatment. The PMNL cultures
were set up directly before rhTNF infusion and immediately
after the infusion. Patients 1-3 were on the schedule with
one rhTNF infusion per week, patients 4-7 received two
rhTNF infusions per week. Whereas in most patients TNF
production decreased immediately after the first rhTNF treat-
ment (with exception of patients 2 and 5) as described
recently (Kist et al., 1988) the changes were not so clear after
repeated rhTNF infusions. TNF levels from non-stimulated
cultures immediately after rhTNF infusion were not lower
compared to pretreatment values in most patients after con-
secutive rhTNF cycles. Only in seven out of 24 such cultures
were TNF levels reduced. About half of the cultures consis-
ting of cells cultured after repeated rhTNF treatment
generated even higher TNF levels compared to the values
immediately before rhTNF infusion (11 out of 24). Only
about half (14 out of 23) of the Staph.a.-stimulated cultures
from patients who had received rhTNF more than once
developed reduced TNF values immediately after rhTNF
infusion during therapy. In eight out of 23 of such stimulated
cultures TNF production was enhanced immediately after
rhTNF infusion (data not shown).
Improvement of the TNF production before each subse-
quent rhTNF infusion as compared to the baseline values
before the very first rhTNF treatment was found in the
course of rhTNF treatment. In all patients the TNF produc-
tion capacity of unstimulated cells as well as a Stapha.a.-
stimulated cells (with the exception of patient 7) increased
during therapy (Figure 1). TNF values were significantly
higher compared to TNF values before any treatment in 17
out of 24 (71%) treatment cycles in unstimulated cultures
(P = 0.014) and in 14 out of 23 (61%) cycles in stimulated
cultures (P = 0.129). Spontaneous TNF production capacity
of all patients was enhanced at some point during rhTNF
therapy.
In three patients TNF production was determined 24 hours
after completion of the rhTNF infusion in seven treatment
cycles (Figure 2). In all but one of the unstimulated cultures
the TNF production increased 24 h after completion of the
infusion and more TNF activity was generated compared to
the pretreatment values. In one culture the level of TNF
produced was unchanged before and 24 h after completion of
the rhTNF infusion. The increase of the TNF levels pro-
duced by unstimulated cultures was statistically significant
(P = 0.158). When the cultures were stimulated with Staph.a.,
three cultures generated higher TNF values, two cultures
produced lower TNF values and one was unchanged 24 h
after rhTNF infusion (P = 0.531).
From PMNL samples of one patient (patient 5) mRNA
was extracted before, directly after and 24 h after rhTNF
infusion in four treatment cycles. In all four cycles the signal
for TNF specific mRNA was strongest 24 h after rhTNF
infusion. Control hybridisation with a human P-actin probe
showed that about equal amounts of RNA had been applied
to the filter (data not shown).
NK activity was determined in subsequent cycles of
therapy before and immediately after rhTNF infusion in four
patients. Again, as already described (Kist et al., 1988) the
NK levels immediately after 24 h of continuous infusion of
rhTNF were always lower compared to the respective NK
value measured before the rhTNF infusion in the same cycle.
However, in all tested cases NK activity significantly in-
creased (P = 0.047) in the course of rhTNF therapy (Figure
3).
Discussion
TNF activates monocytes/macrophages in an autocrine
fashion. The binding of TNF on specific cell surface recep-
tors with subsequent internalization of the ligand appears
necessary for the effects of TNF. Such receptors which bindTNF AS A BIOLOGICAL RESPONSE MODIFIER 587
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Figure 1 TNF production of PMNL from each patient before rhTNF infusions during the course of rhTNF therapy was
determined. Open symbols represent TNF levels of unstimulated cultures and closed symbols represent TNF levels of cultures
stimulated with Staph.a.
TNF with high affinity have recently been described on
human monocytes (Imamura et al., 1987). Considering the
activating function of TNF on human monocytes and also
on NK cells it was surprising to see reduced monokine
production and NK activity in patients immediately after
rhTNF infusion (Kist et al., 1988). The reduction of
monokine production and NK activity might be explained by
the loss of monocytes and NK cells from the circulation as a
consequence of the enhanced leukocyte adherence to the
endothelium after TNF (Bevilacqua et al., 1987). Enhanced
levels of TNF were produced by the PMNL in most cultures
24 h after discontinuation of the rhTNF infusion or in suc-
cessive cycles, and enhanced NK activity in all cultures in the
course of treatment was found. Increased TNF production
was not only measured on the protein level but also the
signal for TNFmRNA of a comparable number of PMNL
was stronger 24 h after completion of the rhTNF therapy.
Thus, the impairment of monocyte function and NK activity
in the peripheral blood induced by rhTNF was a transient
effect which was most pronounced at the first cycle of rhTNF
treatment. The data obtained during later cycles of rhTNF
therapy clearly demonstrated that repeated rhTNF infusions
had an activating effect on TNF production and NK activity
in the peripheral blood. TNF levels of PMNL cultures from
untreated healthy individuals were relatively consistant. Un-
stimulated PMNL cultures contained 0.5 ± 0.5 ng ml-' TNF
and stimulated cultures 14 ± 6 ng ml-' TNF in the super-
natant. NK activity of healthy blood donors was 24 ± 6%.
However, these data were obtained with PMNL from un-
treated healthy individuals and it is questionable whether it is
useful to compare the TNF production capacity and NK
activity of healthy individuals with that of pretreated
patients.
Changes of the investigated parameters in individual
patients during rhTNF therapy seemed to be more infor-
mative. Whether the observed immunomodulatory effect of
rhTNF application can be made persistent for a long time
after rhTNF treatment and whether the effect can be
beneficial for the patient requires further studies. Other
assumptions on changes of the activation state of the
immune system induced by rhTNF seem premature since
only two parameters, TNF production and NK activity, were
determined. Additional studies have to be performed to
establish whether application of rhTNF could become useful
as a biological response modifier.
The authors thank Dr W. Falk for critical reading of the manuscript
and S. Roth for his help with the statistical evaluations.
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Figure 2 TNF production of PMNL before and 24 h after completion of rhTNF infusion. PMNL cultures of patient 1 in the 4th
cycle, patient 2 in the 3rd and 4th cycles, and patient 5 in the 1st, 3rd, 4th and 5th cycles of the rhTNF treatment were established
before (A) or 24 h after completion (B) of the rhTNF infusion. Open bars represent TNF producted by unstimulated cultures and
hatched bars TNF produced by cultures stimulated with Stapha.a. From patient 5 no stimulated culture was established in the 3rd
cycle of rhTNF treatment.
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Figure 3 NK activity of PMNL during rhTNF therapy. NK activity was determined in PMNL cultures from patient 4 in weeks I
and 6, from patient 6 in weeks I and 2, from patient 7 in weeks 2, 5 and 7, and from patient 8 in weeks I and 2 before (open bars)
and after (hatched bars) rhTNF infusion.
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